To Apply Microdosing or Not? Recommendations to Single Out Compounds with Non-Linear Pharmacokinetics Sieto BosgraMaria L. H. VlamingWouter H. J. Vaes Leading Article 05 August 2015 Pages: 1 - 15
A Critical Review of the Current Evidence for Measuring Drug Concentrations of First-Line Agents Used to Treat Tuberculosis in Children Kyle John WilbySara ShabanaFawziah Marra Review Article 16 July 2015 Pages: 17 - 31
Clinical Pharmacokinetic and Pharmacodynamic Profile of Idelalisib Srinivasan RamanathanFeng JinBrian P. Kearney Review Article 05 August 2015 Pages: 33 - 45
Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors Beatrix WulkersdorferMarkus ZeitlingerMonika Schmid Review Article 23 July 2015 Pages: 47 - 77
Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study Adrian DerungsMassimiliano DonzelliManuel Haschke Original Research Article Open access 28 June 2015 Pages: 79 - 91
Population Pharmacokinetic Model of Cabozantinib in Patients with Medullary Thyroid Carcinoma and Its Application to an Exposure-Response Analysis Dale MilesNelson L. JumbeLinh Nguyen Original Research Article 07 July 2015 Pages: 93 - 105
Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation Sarah F. CookJessica K. RobertsJohn N. van den Anker Original Research Article 23 July 2015 Pages: 107 - 119
Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials Mukul MinochaJonathan Q. TranAhmed A. Othman Original Research Article 05 August 2015 Pages: 121 - 130
Comment on: “Enzalutamide: A Step Towards Pharmacokinetic-Based Dosing in Men with Metastatic Castration-Resistant Prostate Cancer” Jacqueline A. Gibbons Letter to the Editor Open access 09 December 2015 Pages: 131 - 132
Comment on: “A Physiologically Based Pharmacokinetic Drug-Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood” Guo-Fu LiXiao GuQing-Shan Zheng Letter to the Editor 09 December 2015 Pages: 133 - 137
Author’s Reply to Zheng et al.: A Physiologically Based Pharmacokinetic Drug–Disease Model to Predict Carvedilol Exposure in Adult and Paediatric Heart Failure Patients by Incorporating Pathophysiological Changes in Hepatic and Renal Blood Flows Muhammad Fawad RasoolFeras KhalilStephanie Läer Letter to the Editor 09 December 2015 Pages: 139 - 141
